Skip to main content
Clinical Trials/NL-OMON41740
NL-OMON41740CompletedPhase 4

The effect of Ivacaftor in CF patients with a class III mutation - TICTAC II study

niversitair Medisch Centrum Utrecht0 sites16 target enrollmentStarted: TBDLast updated:
Conditions

Trial Snapshot

Phase
Phase 4
Status
Completed
Sponsor
Enrollment
16

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Observational

Eligibility Criteria

Ages
2 to 99 (—)

Inclusion Criteria

  • CFTR genotype associated with residual CFTR function;
  • Already had a rectal biopsy to produce an organoid;
  • Start a treatment with Ivacaftor;
  • Male and female patients, aged 6 years or older on the date of informed consent;
  • Signed informed consent form (IC), and where appropriate, signed assent form.

Exclusion Criteria

  • Use of curcumin and or genistein at start or within two weeks prior to start of the study;
  • Inability to follow instructions of the investigator.

Investigators

Sponsor
niversitair Medisch Centrum Utrecht

Similar Trials